Healthcare -
Medical - Devices - NASDAQ - US
$ 1.275
-0.82 %
$ 138 M
Market Cap
-1.03
P/E
1. INTRINSIC VALUE
Balance Sheet
Lucid Diagnostics Inc.
| Current Assets | 25.1 B |
| Cash & Short-Term Investments | 22.4 B |
| Receivables | 405 K |
| Other Current Assets | 2.79 B |
| Non-Current Assets | 5.57 M |
| Long-Term Investments | 0 |
| PP&E | 3.7 M |
| Other Non-Current Assets | 1.87 M |
| Current Liabilities | 23.5 M |
| Accounts Payable | 1.24 M |
| Short-Term Debt | 19.5 M |
| Other Current Liabilities | 2.83 M |
| Non-Current Liabilities | 1.8 M |
| Long-Term Debt | 1.8 M |
| Other Non-Current Liabilities | 0 |
EFFICIENCY
Earnings Waterfall
Lucid Diagnostics Inc.
| Revenue | 4.35 M |
| Cost Of Revenue | 7.1 M |
| Gross Profit | -3.92 M |
| Operating Expenses | 42.1 M |
| Operating Income | -46.1 M |
| Other Expenses | -523 K |
| Net Income | -45.5 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Lucid Diagnostics Inc.
| Net Income | -45.5 M |
| Depreciation & Amortization | 1.17 M |
| Capital Expenditures | -646 K |
| Stock-Based Compensation | 4.53 M |
| Change in Working Capital | -4.43 M |
| Others | -4.41 M |
| Free Cash Flow | -44.8 M |
Wall Street Analysts Price Targets
Lucid Diagnostics Inc.
Wall Street analysts predict an average 1-year price target for LUCD of $2.57 , with forecasts ranging from
a
low of
$2 to a high of $3.5 .
LUCD Lowest Price Target
Wall Street Target
2 USD
56.86%
LUCD Average Price Target
Wall Street Target
2.57 USD
101.68%
LUCD Highest Price Target
Wall Street Target
3.5 USD
174.51%
4. DIVIDEND
ANALYSIS
LUCD does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Lucid Diagnostics Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
915 K USD 1
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes
NEW YORK , May 27, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the Company will join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index, effective after the close of U.S. equity markets on June 27, 2025, as part of their 2025 annual reconstitution, according to a preliminary list of additions posted by FTSE Russell on May 23, 2025. "We are pleased that Lucid is joining these important market indices, which serve as leading benchmarks for institutional investors and as the basis for numerous index-linked financial products," said Dennis McGrath , Lucid's Chief Financial Officer.
prnewswire.com
- 2 weeks ago
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results
Lucid secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Veris Health completed 1Q25 financing, resumed development of implantable physiological monitor, and will soon launch first commercial partnership with major cancer center PAVmed seeking to leverage infrastructure and expand into biopharma sector; actively evaluating clinical and late preclinical stage assets Conference call and webcast to be held today, May 15 th, at 8:30 AM EDT NEW YORK , May 15, 2025 /PRNewswire/ -- PAVmed Inc. (NASDAQ: PAVM) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and reported financial results for the quarter ended March 31, 2025. Conference Call and Webcast The webcast will take place on Thursday, May 15, 2025, at 8:30 AM and is accessible in the investor relations section of the Company's website at pavmed.com.
prnewswire.com
- 1 month ago
Lucid Diagnostics Inc. (LUCD) Q1 2025 Business Update Call Transcript
Lucid Diagnostics Inc. (NASDAQ:LUCD ) Q1 2025 Business Update Conference Call May 14, 2025 8:30 AM ET Company Participants Matt Riley – Senior Director-Investor Relations Lishan Aklog – Chairman and Chief Executive Officer Dennis McGrath – Chief Financial Officer Conference Call Participants Mark Massaro – BTIG Kyle Mikson – Canaccord Genuity Mike Matson – Needham & Company Jeremy Pearlman – Maxim Group Ross Osborn – Cantor Fitzgerald Ed Woo – Ascendiant Capital Operator Good morning and welcome to the Lucid Diagnostics First Quarter 2025 Business Update Conference Call. Please note, this event is being recorded.
seekingalpha.com
- 1 month ago
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue Estimates
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.21 per share a year ago.
zacks.com
- 1 month ago
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results
Processed 3,034 EsoGuard® tests and recognized revenue of $0.8 million in 1Q25 Secured capital to extend runway well past key upcoming reimbursement milestones; ended 1Q25 with over $40 million in proforma cash Conference call and webcast to be held today, May 14 th, at 8:30 AM EDT NEW YORK , May 14, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) ("PAVmed"), today provided a business update for the Company and reported financial results for the three months ended March 31, 2025. Conference Call and Webcast The webcast will take place on Wednesday, May 14, 2025, at 8:30 AM and will be accessible in the investor relations section of the Company's website at luciddx.com.
prnewswire.com
- 1 month ago
Will Lucid Diagnostics Inc. (LUCD) Report Negative Earnings Next Week? What You Should Know
Lucid Diagnostics (LUCD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
- 1 month ago
PAVmed to Hold a Business Update Conference Call and Webcast on May 15, 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , May 1, 2025 /PRNewswire/ -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today announced that it will host a business update conference call and webcast on Thursday, May 15, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D.
prnewswire.com
- 1 month ago
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on May 14, 2025
Conference Call and Webcast at 8:30 AM Eastern Time NEW YORK , April 30, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that it will host a business update conference call and webcast on Wednesday, May 14, 2025, at 8:30 AM ET. During the call, Lishan Aklog, M.D.
prnewswire.com
- 1 month ago
NCI-Sponsored Study Shows Positive Data for Lucid Diagnostics' EsoGuard® Esophageal DNA Test in Patients Without Symptomatic GERD
Study supports expanded indication and market opportunity for EsoGuard esophageal precancer testing NEW YORK , April 24, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced positive data from a National Cancer Institute (NCI)-sponsored study demonstrating that its EsoGuard® Esophageal DNA Test can effectively detect esophageal precancer (Barrett's Esophagus or BE) among at-risk patients without symptoms of chronic gastroesophageal reflux disease (GERD), such as heartburn. These results support EsoGuard esophageal precancer testing in an expanded target population, consistent with existing American Gastroenterological Association (AGA) guidelines and has the potential to substantially increase the market opportunity.
prnewswire.com
- 1 month ago
Lucid Diagnostics: DNA Testing To Get Medicare Coverage, Driving Volumes, Says Bullish Analyst
According to Needham, Lucid Diagnostics Inc. LUCD is likely to receive approval for EsoGuard testing-related Medicare reimbursement, which would boost testing volumes.
benzinga.com
- 2 months ago
Lucid Diagnostics Announces Closing of Public Offering of Common Stock
NEW YORK , April 11, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the closing of its previously announced underwritten public offering of 14,375,000 shares of its common stock, including 1,875,000 shares issued pursuant to the exercise of the underwriters' option to purchase additional shares, at a public offering price of $1.20 per share. The total net proceeds from the offering, after deducting the underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $16.1 million.
prnewswire.com
- 2 months ago
Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
NEW YORK , April 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the pricing of its underwritten public offering of 12,500,000 shares of its common stock at a public offering price of $1.20 per share. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 1,875,000 shares of common stock at the public offering price, less underwriting discounts and commissions.
prnewswire.com
- 2 months ago
8. Profile
Summary
Lucid Diagnostics Inc. LUCD
COUNTRY
US
INDUSTRY
Medical - Devices
MARKET CAP
$ 138 M
Dividend Yield
0.00%
Description
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Contact
One Grand Central Place, New York City, NY, 10165
https://www.luciddx.com
IPO
Date
Oct. 14, 2021
Employees
72
Officers
Helen Moinova Ph.D.
Co-Founder & Strategic Advisor
Mr. Shaun M. O'Neill M.B.A.
President & Chief Operating Officer
Dr. Lishan Aklog M.D.
Chairman & Chief Executive Officer
Mr. Dennis M. McGrath CPA
Chief Financial Officer
Dr. Suman M. Verma M.D., Ph.D.
Chief Scientific Officer
Dr. Sanford D. Markowitz M.D., Ph.D.
Co-Founder & Strategic Advisor
Dr. Amitabh Chak M.D.
Co-Founder & Strategic Advisor
Dr. Brian J. deGuzman M.D.
Chief Technology & Compliance Officer
Mr. Michael Adam Gordon
General Counsel & Secretary
Dr. Joseph Willis M.D.
Co-founder & Strategic Advisor